Abstracts tagged "psoriatic arthritis and spondylarthropathy"

Abstract Number: 2609 • 2018 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
Dalifer Freites Núñez¹, Zulema Rosales Rosado^1,2, Judit Font Urgelles², Isabel Hernández-Rodríguez², Leticia Leon¹, Gloria Candelas Rodriguez², Luis Rodriguez-Rodriguez¹, Benjamín Fernández-Gutiérrez^1,2, Juan A Jover Jover² and Lydia A Alcazar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that benefits from DMARDs, in this regard knowing more about these therapies is a great step…
Abstract Number: 1232 • 2017 ACR/ARHP Annual Meeting
The Perceived Impact of Recent-Onset Psoriatic Arthritis Is Different between Genders: A Spanish Multicenter Experience
Rubén Queiro¹, Ana Laiz², Carlos Alberto Montilla-Morales³, Eva Galindez-Agirregoikoa⁴, Juan J. Bethencourt⁵ and Daniel Seoane⁶, ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology, HU. Santa Creu i San Pau, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁴Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Rheumatology, HU. Canarias, Sta. Cruz de Tenerife, Spain, ⁶Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
Background/Purpose: Some studies point to a differential clinical expression between men and women with PsA, but the information on gender differences is very scarce in…
Abstract Number: 2525 • 2017 ACR/ARHP Annual Meeting
Influence of Cardiovascular Comorbidity on Achieving Therapeutic Goals: A Comparative Study between Recent-Onset Psoriatic Arthritis and Established Disease
Rubén Queiro¹ and Juan D. Cañete², ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Some cardiovascular risk factors (CVRF) have been associated with a lower probability of achieving a good therapeutic response in PsA1. However, the reason for…
Abstract Number: 959 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
Philip J Mease¹, Masato Okada², Mitsumasa Kishimoto², Catherine L. Shuler³, Hilde Carlier³, Chen-Yen Lin³, Jiani Mou³, Susan R Moriarty³, Chin H. Lee³ and Dafna D Gladman⁴, ¹Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is an IgG4 monoclonal antibody that binds with high affinity and specificity to the proinflammatory cytokine IL-17A. In this phase 3 study…
Abstract Number: 2744 • 2016 ACR/ARHP Annual Meeting
Utilization of the Psoriasis Epidemiology Screening Tool (PEST) Questionnaire to Detect Psoriatic Arthritis in Clinical Practice: Data from the Validation of Psoriatic Arthritis Screening Tool for Korean Psoriasis Patients (VALOR) Study
You Jung Ha¹, Soyun Cho², Sang Heon Lee³, Yong Beom Choe⁴, Tae-Hwan Kim⁵, Joo Yeon Ko⁶, Sung Jae Choi⁷, Il-Hwan Kim⁸, Sang Woong Youn⁹ and Kichul Shin¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ²Department of Dermatology, Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of, ³Department of Internal Medicine,Division of Rheumatology., Division of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, The Republic of, ⁴Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea, The Republic of, ⁵Department of Rheumatology, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Department of Dermatology, Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea, The Republic of, ⁷Division of Rheumatology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea, The Republic of, ⁸Department of Dermatology, Korea University Ansan Hospital, Ansan, Korea, The Republic of, ⁹Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, ¹⁰Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of
Background/Purpose: Several questionnaires have been developed to help identify psoriatic arthritis (PsA) among patients with psoriasis (PsO), but there is no screening tool yet tested…
Abstract Number: 1737 • 2015 ACR/ARHP Annual Meeting
Increased Osteoclast Precursors with an Elevated DC-STAMP Expression May Identify Psoriasis Patients at Risk for Psoriatic Arthritis
Yahui Grace Chiu¹, Sutha Shanmugarajah², Dongge Li³, Megan Freiburger⁴, Sharon Moorehead⁵, Dafna Gladman⁶ and Christopher T. Ritchlin⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Toronto Western Hospital, Toronto, ON, Canada, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Biology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁷Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop into psoriatic arthritis (PsA) within 10 years. This Ps-to-PsA transition paradigm provides a unique opportunity to recognize…
Abstract Number: 1742 • 2015 ACR/ARHP Annual Meeting
Fingerprint Biomarkers of Type I and III Collagen in Axial Spondyloarthropathy (axSpA) and Psoriatic Arthritis (PsA). Association with Disease Activity and Diagnostic Capacity
Natasja Stæhr Gudman¹, Anne Friesgaard Christensen², Grith Lykke Sørensen³, Anne C. Bay-Jensen⁴, Anne Sofie Siebuhr⁵, Morten Asser Karsdal⁶, Heidi Lausten Munk⁷, Leif Ejstrup⁸, Anne Gitte Loft⁹ and Peter Junker¹⁰, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Rheumatology, Odense University Hospital, Odense, Denmark, ³Cardiovascular and Renal Research, Institute of Molecular Medicin, University of Southern Denmark, Odense, Denmark, ⁴Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁶Research & Development, Nordic Bioscience, Herlev, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁸Odense University Hosp, SDR Blvd, Odense, Denmark, ⁹Department of Rheumatology, Vejle Hospital, Vejle, Denmark, ¹⁰University of Southern Denmark, Odense, Denmark
Background/Purpose: AxSpA and PsA are core members of the spondyloarthritis complex. One cardinal characteristic shared by these two conditions is increased remodeling of bone and…
Abstract Number: 2867 • 2015 ACR/ARHP Annual Meeting
Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study
Vibeke Strand¹, M. Elaine Husni², Zheng-Yi Zhou³, James Signorovitch³, Jenny Griffith⁴, Yichen Zhong³ and Arijit Ganguli⁴, ¹Stanford University, Palo Alto, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group, Inc., Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Progression of psoriatic arthritis (PsA) can lead to irreversible joint damage and functional impairment. TNF inhibitors (TNFi’s) have been shown to improve signs and…
Abstract Number: 1581 • 2014 ACR/ARHP Annual Meeting
Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis Is Suggestive of Undiagnosed Spondyloarthropathies
Majed Khraishi¹, Heather Jones^2,3 and Annette Szumski⁴, ¹Clinical Professor of Medicine (Rheumatology), Memorial University of Newfoundland, St. John's, NF, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Patients with psoriasis (Ps) and/or psoriatic arthritis (PsA) may have clinical features suggestive of axial skeletal abnormalities and should be assessed for the presence…
Abstract Number: 629 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Chondrocyte Activity Are Increased in Psoriasis Arthritis and Spondyloarthritis
Natasja Stæhr Gudman¹, Heidi Lausten Munk², Anne Friesgaard Christensen³, Leif Ejstrup⁴, Grith Lykke Sørensen⁵, Anne Gitte Loft³, Morten A. Karsdal⁶, Anne C. Bay-Jensen⁷, Yi He⁸, Anne Sofie Siebuhr⁹ and Peter Junker², ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Department of Rheumatology, Odense University Hospital, Odense, Denmark, ³Department of Rheumatology, Vejle Hospital, Vejle, Denmark, ⁴Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark, ⁵Cardiovascular and Renal Research, Institute of Molecular Medicin, University of Southern Denmark, Odense, Denmark, ⁶Research & Development, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁷Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁸Nordic Bioscience, Herlev, Denmark, ⁹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: Psoriasis arthritis (PsA) and spondyloarthritis (SpA) are both inflammatory joint diseases in which the pathogenesis is not fully understood. However, both pathologies are associated…
Abstract Number: 568 • 2014 ACR/ARHP Annual Meeting
Secondary Amyloidosis Complicating Spondyloarthritis: Still Present after All These Years
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Susana Holgado¹, Maria Lourdes Mateo¹, Juana Sanint¹, Anne Riveros-Frutos², Jeronima Cañellas¹, Xavier Tena¹ and Alejandro Olivé Marqués¹, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Secondary amyloidosis (AA) is a disorder caused by deposition of insoluble amyloid A fibrils in different tissues and organs. It is a rare and…
Abstract Number: 345 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity In Psoriatic Arthritis Patients: Impact Of Treatment With TNF Inhibitors In a Real-World Canadian Population
Proton Rahman¹, Denis Choquette², William G. Bensen³, Majed M. Khraishi⁴, Isabelle Fortin⁵, Andrew Chow⁶, Maqbool K. Sheriff⁷, Julie Vaillancourt⁸, John S. Sampalis⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁶University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: To determine the point prevalence of peri-articular manifestations (PAMs) in psoriatic arthritis (PsA) patients treated with anti-TNF in a real-world, Canadian, routine clinical practice…
Abstract Number: 1360 • 2012 ACR/ARHP Annual Meeting
Spinal Involvement in Axial Psoriatic Artritis Is Not Determined by the Presence of HLA-B27. Is the HLA-B27 Arm of the Axial Spa Criteria Reliable for Classifying Axial Psoriatic Arthritis?
Jose Luis Fernandez-Sueiro¹, JA Pinto¹, S. Pertega-Diaz², E. Gonzalez³, Ignacio Rego-Perez⁴, Francisco J. de Toro-Santos⁵ and Francisco J. Blanco V⁶, ¹Rheumatology Division, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ²Epidemiology and Statistics, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ³Rheumatology, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ⁴INIBIC-Hospital Universitario A Coruña. Genomic Group. Rheumatology Division., A Coruña, Spain, ⁵Reumatology, Complejo Hospitalario Universitario Juan Canalejo, Universidad de la Coruña, La Coruña, Spain, ⁶Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: There is a debate whether axial psoriatic arthritis (axPsA) is an ankylosing spondylitis with psoriasis, however due to the fact that PsA has characteristic…
Abstract Number: 1026 • 2012 ACR/ARHP Annual Meeting
Psoriatic Arthritis and Spondyloarthritis: Inflammation Assessed by “Head to Toe” Wholebody Magnetic Resonance Imaging – A Comparison with Clinical Joint Examination
René Panduro Poggenborg¹, Susanne Juhl Pedersen², Iris Eshed³, Inge Juul Sørensen⁴, Ole Rintek Madsen⁵, J.M. Møller⁶ and Mikkel Østergaard⁷, ¹Department of Rheumatology, Copenhagen University Hospital in Glostrup, Copenhagen, Denmark, ²Dept. of Rheumatology, Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Department of Radiology, Sheba Medical Center, Tel Hashomer, Israel, ⁴Department of Rheumatology, Glostrup Hospital, Copenhagen, Denmark, ⁵Department of Rheumatology, Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, ⁶Department of Radiology, Copenhagen University Hospital in Herlev, Copenhagen, Denmark, ⁷Copenhagen University Hospital Glostrup, Glostrup, Denmark
Background/Purpose: Psoriatic arthritis (PsA) and spondyloarthritis (SpA) is associated with a varied pattern of axial and peripheral inflammation. Wholebody magnetic resonance imaging (WBMRI) is a…
Abstract Number: 596 • 2012 ACR/ARHP Annual Meeting
Evolution of Atherosclerosis in Psoriatic Arthritis: Is the Former an Independent Inflammatory Process?
Roberta Ramonda¹, Massimo Puato², Valentina Modesti³, Mariagrazia Lorenzin⁴, Paola Frallonardo⁴, Augusta Ortolan⁴, Carla Campana³, Alessandro Lo Nigro³ and Leonardo Punzi⁵, ¹Rheumatology Unit, University of Padova, Padova, Italy, ²Department of Internal Medicine, University of Padova, Padova, Italy, ³Unit of Rheumatology, University of Padova, Padova, Italy, ⁴Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ⁵Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: A non-invasive study focusing on the structural and functional properties of the carotid arteries was carried out in psoriatic arthritis (PsA) patients. Increased cardiovascular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].